Polymer- and Lipid-Based Nanostructured Drug Delivery Systems for the Treatment of CNS Diseases: Recent Advances towards Clinical Application, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 2677

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy-Drug Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy
Interests: brain targeting; nasal route; mucoadhesion; nanoparticles from renewable polymers; self-emulsifying lipid based drug delivery system; polymer-small molecule drug conjugates; cyclodextrins
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Central Nervous System (CNS) is the most complex organ of the human body and, consequently, remarkable challenges must be tackled in the therapeutic treatment of neurological disorders, the most relevant being the crossing of the blood–brain barrier (BBB). At present, the treatment of CNS diseases is mainly symptomatic and there are no disease-modifying therapies for most of these disorders. In this context, it appears necessary not only to create more effective drugs but also to improve their corresponding delivery systems, particularly when complex drugs, including genes, antibodies, peptides, and proteins, as well as neurotrophic factors and stem cells for regenerative therapy, are to be administered. For this last purpose, in the last few decades, several nanostructured biomaterials have been identified as tools for the preparation of advanced drug delivery systems that could potentially be useful for treating neurological disorders. The main advantages of using such nanostructured biomaterials in the neurological field are the satisfactory overcoming of the BBB and their biocompatibility. Current research in this area is focused on slowing down disease progression to achieve the important goal of improving the quality of life of patients.

For this Special Issue, in particular, we call to researchers involved in brain targeting, overcoming the BBB both by invasive (e.g., brain implants, BBB transient opening etc.), and non-invasive methods (prodrugs, intranasal administration route (i.e., nose-to-brain delivery) etc.) using different materials such as polymers and lipids from natural and renewable resources to participate. These raw materials can be used as such or in physical mixtures to provide advanced nanostructured drug delivery systems (DDS), including polymeric nanoparticles, micelles, hydrogels, and lipid nanocarriers (liposomes, solid lipid nanoparticles and nanostructured lipid carriers). Moreover, such nanostructured DDSs can be appropriately functionalized with suitable molecules to provide particular properties such as brain targeting or stability in biological fluids. A relevant application of such functionalized nanostructured DDSs is in the treatment of the most aggressive brain tumours, which are characterized by an unfavourable prognosis. The mentioned materials can be also used as scaffolds for the transplantation of stem cells (neural, pluripotent, or mesenchymal) to induce and promote the regeneration of damaged neuronal cells in neurodegenerative diseases by secreting growth factors and the exosomes derived thereof.

For this Special Issue, original research articles and reviews on the status, challenges, and recent advances in polymer- and lipid-based nanostructured formulations used for the treatment of neurological disorders are welcome, as well as scientific papers on the diagnostic applications of these nanosized DDSs.

We look forward to receiving your contributions.

Prof. Dr. Giuseppe Trapani
Prof. Dr. Massimo Conese
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegenerative diseases
  • neurological diseases
  • brain tumors
  • brain targeting
  • nose-to-brain delivery
  • polymers from natural and renewable resources
  • polymer/lipid nanoparticles
  • neurotrophic factors
  • stem cells
  • exosomes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 2134 KiB  
Article
Dopamine and Citicoline-Co-Loaded Solid Lipid Nanoparticles as Multifunctional Nanomedicines for Parkinson’s Disease Treatment by Intranasal Administration
by Stefano Castellani, Giorgia Natalia Iaconisi, Francesca Tripaldi, Vito Porcelli, Adriana Trapani, Eugenia Messina, Lorenzo Guerra, Cinzia Di Franco, Giuseppe Maruccio, Anna Grazia Monteduro, Filomena Corbo, Sante Di Gioia, Giuseppe Trapani and Massimo Conese
Pharmaceutics 2024, 16(8), 1048; https://doi.org/10.3390/pharmaceutics16081048 - 7 Aug 2024
Cited by 2 | Viewed by 1440
Abstract
This work aimed to evaluate the potential of the nanosystems constituted by dopamine (DA) and the antioxidant Citicoline (CIT) co-loaded in solid lipid nanoparticles (SLNs) for intranasal administration in the treatment of Parkinson disease (PD). Such nanosystems, denoted as DA-CIT-SLNs, were designed according [...] Read more.
This work aimed to evaluate the potential of the nanosystems constituted by dopamine (DA) and the antioxidant Citicoline (CIT) co-loaded in solid lipid nanoparticles (SLNs) for intranasal administration in the treatment of Parkinson disease (PD). Such nanosystems, denoted as DA-CIT-SLNs, were designed according to the concept of multifunctional nanomedicine where multiple biological roles are combined into a single nanocarrier and prepared by the melt emulsification method employing the self-emulsifying Gelucire® 50/13 as lipid matrix. The resulting DA-CIT-SLNs were characterized regarding particle size, surface charge, encapsulation efficiency, morphology, and physical stability. Differential scanning calorimetry, FT-IR, and X ray diffraction studies were carried out to gain information on solid-state features, and in vitro release tests in simulated nasal fluid (SNF) were performed. Monitoring the particle size at two temperatures (4 °C and 37 °C), the size enlargement observed over the time at 37 °C was lower than that observed at 4 °C, even though at higher temperature, color changes occurred, indicative of possible neurotransmitter decomposition. Solid-state studies indicated a reduction in the crystallinity when DA and CIT are co-encapsulated in DA-CIT-SLNs. Interestingly, in vitro release studies in SNF indicated a sustained release of DA. Furthermore, DA-CIT SLNs displayed high cytocompatibility with both human nasal RPMI 2650 and neuronal SH-SY5Y cells. Furthermore, OxyBlot assay demonstrated considerable potential to assess the protective effect of antioxidant agents against oxidative cellular damage. Thus, such protective effect was shown by DA-CIT-SLNs, which constitute a promising formulation for PD application. Full article
Show Figures

Figure 1

Back to TopTop